AIM:To assess the anti-cancer effect of lobaplatin on human gastric cancer cells,and to explore the underlying molecular mechanisms.METHODS:The human gastric cancer cell lines MKN-28,AGS and MKN-45 were used.The cytot...AIM:To assess the anti-cancer effect of lobaplatin on human gastric cancer cells,and to explore the underlying molecular mechanisms.METHODS:The human gastric cancer cell lines MKN-28,AGS and MKN-45 were used.The cytotoxicity of lobaplatin was detected using an MTS cell proliferation assay.Flow cytometry was used to detect cell apoptosis using Annexin V-FITC Apoptosis Detection Kit.The expression of apoptosis-regulated genes was examined at the protein level using Western blot.RESULTS:Lobaplatin inhibited the proliferation of human gastric cancer cells and induced apoptosis,which may be associated with the up-regulation of Bax expression,poly(ADP-ribose)polymerase(PARP)cleavage,p53 expression and the reduction of Bcl-2 expression.CONCLUSION:The cytotoxicity of lobaplatin may be due to its ability of inducing apoptosis of gastric cancer cells,which would support the potential use of lobaplatin for the therapy of gastric cancer.展开更多
BACKGROUND Drug-eluting beads show good safety and promising efficacy when used as part of a transarterial chemoembolization regimen for primary liver cancer.However,data on the clinical efficacy and safety of pirarub...BACKGROUND Drug-eluting beads show good safety and promising efficacy when used as part of a transarterial chemoembolization regimen for primary liver cancer.However,data on the clinical efficacy and safety of pirarubicin-loaded beads combined with lobaplatin are lacking in China.AIM To evaluate the efficacy and safety of transcatheter arterial chemoembolization using pirarubicin-loaded beads combined with lobaplatin for primary liver cancer.METHODS Between January 2019 and March 2020,60 patients with primary liver cancer were selected at Hebei North University Affiliated First Hospital.According to different treatment methods,the participants were categorized into two groups with 30 patients treated with pirarubicin-loaded microspheres combined with lobaplatin included in an observation group and 30 patients treated with pirarubicin emulsion with lipiodol combined with lobaplatin were included in a control group.The progression-free survival,overall survival,clinical response rate,disease control rate,liver and kidney function and adverse reactions were compared between the two groups.RESULTS The progression-free survival was 14 mo in the observation group,which was significantly higher than 9 mo of the control group(P<0.05).The 6-mo,12-mo and 18-mo survival rates were 93.33%(28/30),66.67%(20/30)and 23.33%(7/30),respectively in the observation group,which were significantly higher than 83.33%(25/30),50.00%(15/30)and 13.33%(4/30),respectively,of the control group(all P<0.05).The clinical efficacy rate and disease control rate were 73.33%and 93.33%,respectively,in the observation group,which were significantly higher than those of the control group(53.55%and 80.00%,respectively,all P<0.05).There was no significant difference in alpha-fetoprotein between the two groups before the treatment(P>0.05).After the treatment,alpha-fetoprotein was 289.06±76.21 ng/m L in the observation group and 365.01±73.11 ng/m L in the control group,which were low in both groups compared with those before the treatment(all P<0.05).The incidence of nausea and vomiting was significantly lower in the observation group than in the control group(P<0.05).There was no significant difference for the adverse reactions of pain and fever between the two groups(P<0.05).CONCLUSION The combination of pirarubicin-loaded beads and lobaplatin can improve treatment efficacy resulting in mild liver function damage and postoperative complications in patients with primary liver cancer.It can be used in clinical practice.展开更多
BACKGROUND Albumin-bound paclitaxel(ABP)has been used as second-and higher-line treatments for advanced esophageal cancer,and its efficacy and safety have been well demonstrated.Lobaplatin(LBP)is a third-generation pl...BACKGROUND Albumin-bound paclitaxel(ABP)has been used as second-and higher-line treatments for advanced esophageal cancer,and its efficacy and safety have been well demonstrated.Lobaplatin(LBP)is a third-generation platinum antitumor agent;compared with the first two generations of platinum agents,it has lower toxicity and has been approved for the treatment of breast cancer,small cell lung cancer,and chronic granulocytic leukemia.However,its role in the treatment of esophageal cancer warrants further investigations.AIM To investigate the efficacy and safety of induction chemotherapy with ABP plus LBP followed by concurrent radiochemotherapy(RCT)for locally advanced esophageal cancer.METHODS Patients with pathologically confirmed advanced esophageal squamous cell carcinoma(ESCC)at our hospital were enrolled in this study.All patients were treated with two cycles of induction chemotherapy with ABP plus LBP followed by concurrent RCT:ABP 250 mg/m^(2),ivgtt,30 min,d1,every 3 wk;and LBP,30 mg/m^(2),ivgtt,2 h,d1,every 3 wk.A total of four cycles were scheduled.The dose of the concurrent radiotherapy was 56-60 Gy/28-30 fractions,1.8-2.0 Gy/fraction,and 5 fractions/wk.RESULTS A total of 29 patients were included,and 26 of them completed the treatment protocol.After the induction chemotherapy,the objective response rate(ORR)was 61.54%,the disease control rate(DCR)was 88.46%,and the progressive disease(PD)rate was 11.54%;after the concurrent RCT,the ORR was 76.92%,the DCR was 88.46%,and the PD rate was 11.54%.The median progression-free survival was 11.1 mo and the median overall survival was 15.83 mo.Cox multivariate analysis revealed that two cycles of induction chemotherapy followed by concurrent RCT significantly reduced the risk of PD compared with two cycles of chemotherapy alone(P=0.0024).Non-hematologic toxicities were tolerable,and the only grade 3 non-hematologic toxicity was radiation-induced esophagitis(13.79%).The main hematologic toxicity was neutropenia,and no grade 4 adverse event occurred.CONCLUSION Induction chemotherapy with ABP plus LBP followed by concurrent RCT is effective in patients with locally advanced ESCC,with mild adverse effects.Thus,this protocol is worthy of clinical promotion and application.展开更多
To investigate the adverse reactions and efficacy of docetaxel combined with lobaplatin in adjuvant chemotherapy for triple-negative breast cancer in elderly patients.A total of 96 elderly triple-negative breast cance...To investigate the adverse reactions and efficacy of docetaxel combined with lobaplatin in adjuvant chemotherapy for triple-negative breast cancer in elderly patients.A total of 96 elderly triple-negative breast cancer patients admitted to our hospital from January 2008 to December 2011 were randomly divided into two groups.A group of 56 patients received docetaxel 75 mg·m^(-2),intravenous drip,d1;lobaplatin 30 mg·m^(-2),intravenous drip,d1;21 days repeat,a total of 6 cycles.A group of 40 patients received chemotherapy for 6 cycles with an anthracycline-containing(TEC)regimen.Comparison of adverse reactions and 5-year diseasefree survival in both groups.The incidence of thrombocytopenia was significantly higher in 56 patients with TL regimen than those with TCE-containing anthracyclines(P=0.005).But the incidence of cardiotoxicity was 32.5%in the TEC group.And the difference was statistically significant(P=0.008).The 5-year disease-free survival rate was 73.2%in the TL group and 67.5%in the TEC group.There was no statistical difference.Docetaxel combined with lobaplatin in the treatment of elderly triple-negative breast cancer has no significant difference in efficacy compared with traditional anthracycline-containing drugs,but it can avoid the cardiotoxicity caused by anthracyclines.It’s a new option for elderly TNBC adjuvant chemotherapy,suggesting to expand the sample content for further research.展开更多
目的探讨住院人群中注射用洛铂相关血小板减少的临床特征及影响因素,为临床安全合理用药提供参考。方法基于“医疗机构药物不良事件主动监测与智能评估警示系统(adverse drug event active surveillance and assessment system,ADE-ASAS...目的探讨住院人群中注射用洛铂相关血小板减少的临床特征及影响因素,为临床安全合理用药提供参考。方法基于“医疗机构药物不良事件主动监测与智能评估警示系统(adverse drug event active surveillance and assessment system,ADE-ASAS)”回顾性监测2012年1月1日至2019年12月31日期间本院使用注射用洛铂(10 mg)的住院病例,分析其相关血小板减少的发生特征,采用倾向性评分匹配(propensity score matching,PSM)的方法选取对照组以探究相关影响因素。结果4899例使用注射用洛铂的住院患者中,360例发生血小板减少,发生率为7.35%;Logistic回归模型分析结果显示注射用洛铂相关血小板减少的影响因素主要包括既往洛铂用药史(OR:2.967;95%CI:1.676~5.250)、合并使用吡柔比星(OR:3.634;95%CI:1.355~9.750)以及血小板基值(OR:0.955;95%CI:0.947~0.962)。结论ADE-ASAS可精准高效地获取大样本目标用药人群的真实世界数据;注射用洛铂相关血小板减少属于常见的不良反应;临床使用注射用洛铂应关注既往使用过该药的患者,谨慎联用抗肿瘤、抗菌特别是蒽环类药物(如吡柔比星),加强血小板计数监测。展开更多
基金Supported by National Natural Science Foundation of China,No.81101648
文摘AIM:To assess the anti-cancer effect of lobaplatin on human gastric cancer cells,and to explore the underlying molecular mechanisms.METHODS:The human gastric cancer cell lines MKN-28,AGS and MKN-45 were used.The cytotoxicity of lobaplatin was detected using an MTS cell proliferation assay.Flow cytometry was used to detect cell apoptosis using Annexin V-FITC Apoptosis Detection Kit.The expression of apoptosis-regulated genes was examined at the protein level using Western blot.RESULTS:Lobaplatin inhibited the proliferation of human gastric cancer cells and induced apoptosis,which may be associated with the up-regulation of Bax expression,poly(ADP-ribose)polymerase(PARP)cleavage,p53 expression and the reduction of Bcl-2 expression.CONCLUSION:The cytotoxicity of lobaplatin may be due to its ability of inducing apoptosis of gastric cancer cells,which would support the potential use of lobaplatin for the therapy of gastric cancer.
基金Supported by Zhangjiakou Science and Technology Research and Development Program,No.1821154HZhangjiakou Technology Innovation Guidance Program,No.2021194H。
文摘BACKGROUND Drug-eluting beads show good safety and promising efficacy when used as part of a transarterial chemoembolization regimen for primary liver cancer.However,data on the clinical efficacy and safety of pirarubicin-loaded beads combined with lobaplatin are lacking in China.AIM To evaluate the efficacy and safety of transcatheter arterial chemoembolization using pirarubicin-loaded beads combined with lobaplatin for primary liver cancer.METHODS Between January 2019 and March 2020,60 patients with primary liver cancer were selected at Hebei North University Affiliated First Hospital.According to different treatment methods,the participants were categorized into two groups with 30 patients treated with pirarubicin-loaded microspheres combined with lobaplatin included in an observation group and 30 patients treated with pirarubicin emulsion with lipiodol combined with lobaplatin were included in a control group.The progression-free survival,overall survival,clinical response rate,disease control rate,liver and kidney function and adverse reactions were compared between the two groups.RESULTS The progression-free survival was 14 mo in the observation group,which was significantly higher than 9 mo of the control group(P<0.05).The 6-mo,12-mo and 18-mo survival rates were 93.33%(28/30),66.67%(20/30)and 23.33%(7/30),respectively in the observation group,which were significantly higher than 83.33%(25/30),50.00%(15/30)and 13.33%(4/30),respectively,of the control group(all P<0.05).The clinical efficacy rate and disease control rate were 73.33%and 93.33%,respectively,in the observation group,which were significantly higher than those of the control group(53.55%and 80.00%,respectively,all P<0.05).There was no significant difference in alpha-fetoprotein between the two groups before the treatment(P>0.05).After the treatment,alpha-fetoprotein was 289.06±76.21 ng/m L in the observation group and 365.01±73.11 ng/m L in the control group,which were low in both groups compared with those before the treatment(all P<0.05).The incidence of nausea and vomiting was significantly lower in the observation group than in the control group(P<0.05).There was no significant difference for the adverse reactions of pain and fever between the two groups(P<0.05).CONCLUSION The combination of pirarubicin-loaded beads and lobaplatin can improve treatment efficacy resulting in mild liver function damage and postoperative complications in patients with primary liver cancer.It can be used in clinical practice.
文摘BACKGROUND Albumin-bound paclitaxel(ABP)has been used as second-and higher-line treatments for advanced esophageal cancer,and its efficacy and safety have been well demonstrated.Lobaplatin(LBP)is a third-generation platinum antitumor agent;compared with the first two generations of platinum agents,it has lower toxicity and has been approved for the treatment of breast cancer,small cell lung cancer,and chronic granulocytic leukemia.However,its role in the treatment of esophageal cancer warrants further investigations.AIM To investigate the efficacy and safety of induction chemotherapy with ABP plus LBP followed by concurrent radiochemotherapy(RCT)for locally advanced esophageal cancer.METHODS Patients with pathologically confirmed advanced esophageal squamous cell carcinoma(ESCC)at our hospital were enrolled in this study.All patients were treated with two cycles of induction chemotherapy with ABP plus LBP followed by concurrent RCT:ABP 250 mg/m^(2),ivgtt,30 min,d1,every 3 wk;and LBP,30 mg/m^(2),ivgtt,2 h,d1,every 3 wk.A total of four cycles were scheduled.The dose of the concurrent radiotherapy was 56-60 Gy/28-30 fractions,1.8-2.0 Gy/fraction,and 5 fractions/wk.RESULTS A total of 29 patients were included,and 26 of them completed the treatment protocol.After the induction chemotherapy,the objective response rate(ORR)was 61.54%,the disease control rate(DCR)was 88.46%,and the progressive disease(PD)rate was 11.54%;after the concurrent RCT,the ORR was 76.92%,the DCR was 88.46%,and the PD rate was 11.54%.The median progression-free survival was 11.1 mo and the median overall survival was 15.83 mo.Cox multivariate analysis revealed that two cycles of induction chemotherapy followed by concurrent RCT significantly reduced the risk of PD compared with two cycles of chemotherapy alone(P=0.0024).Non-hematologic toxicities were tolerable,and the only grade 3 non-hematologic toxicity was radiation-induced esophagitis(13.79%).The main hematologic toxicity was neutropenia,and no grade 4 adverse event occurred.CONCLUSION Induction chemotherapy with ABP plus LBP followed by concurrent RCT is effective in patients with locally advanced ESCC,with mild adverse effects.Thus,this protocol is worthy of clinical promotion and application.
基金Natural Science Fund of Xinjiang Uygur Autonomous Region(2017D01C407)。
文摘To investigate the adverse reactions and efficacy of docetaxel combined with lobaplatin in adjuvant chemotherapy for triple-negative breast cancer in elderly patients.A total of 96 elderly triple-negative breast cancer patients admitted to our hospital from January 2008 to December 2011 were randomly divided into two groups.A group of 56 patients received docetaxel 75 mg·m^(-2),intravenous drip,d1;lobaplatin 30 mg·m^(-2),intravenous drip,d1;21 days repeat,a total of 6 cycles.A group of 40 patients received chemotherapy for 6 cycles with an anthracycline-containing(TEC)regimen.Comparison of adverse reactions and 5-year diseasefree survival in both groups.The incidence of thrombocytopenia was significantly higher in 56 patients with TL regimen than those with TCE-containing anthracyclines(P=0.005).But the incidence of cardiotoxicity was 32.5%in the TEC group.And the difference was statistically significant(P=0.008).The 5-year disease-free survival rate was 73.2%in the TL group and 67.5%in the TEC group.There was no statistical difference.Docetaxel combined with lobaplatin in the treatment of elderly triple-negative breast cancer has no significant difference in efficacy compared with traditional anthracycline-containing drugs,but it can avoid the cardiotoxicity caused by anthracyclines.It’s a new option for elderly TNBC adjuvant chemotherapy,suggesting to expand the sample content for further research.
文摘目的探讨住院人群中注射用洛铂相关血小板减少的临床特征及影响因素,为临床安全合理用药提供参考。方法基于“医疗机构药物不良事件主动监测与智能评估警示系统(adverse drug event active surveillance and assessment system,ADE-ASAS)”回顾性监测2012年1月1日至2019年12月31日期间本院使用注射用洛铂(10 mg)的住院病例,分析其相关血小板减少的发生特征,采用倾向性评分匹配(propensity score matching,PSM)的方法选取对照组以探究相关影响因素。结果4899例使用注射用洛铂的住院患者中,360例发生血小板减少,发生率为7.35%;Logistic回归模型分析结果显示注射用洛铂相关血小板减少的影响因素主要包括既往洛铂用药史(OR:2.967;95%CI:1.676~5.250)、合并使用吡柔比星(OR:3.634;95%CI:1.355~9.750)以及血小板基值(OR:0.955;95%CI:0.947~0.962)。结论ADE-ASAS可精准高效地获取大样本目标用药人群的真实世界数据;注射用洛铂相关血小板减少属于常见的不良反应;临床使用注射用洛铂应关注既往使用过该药的患者,谨慎联用抗肿瘤、抗菌特别是蒽环类药物(如吡柔比星),加强血小板计数监测。
